Revolutionising Diabetes Care

Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.
Picture: Associate Professor Neale Cohen

Revolutionising Diabetes Care

July 1, 2026
Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.
Read Transcript

The challenge

Diabetes is a significant health challenge in remote communities, where access to healthcare can be limited and health outcomes are often worse than in the broader population.

According to the Australian Institute of Health and Welfare, diabetes has a significant health and economic impact in Australia, costing Australia's health system more than $4 billion each year. In remote communities, the burden is even greater, increasing the risk of serious complications including heart disease, kidney disease and premature death.

Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.

Project overview 

Researchers are testing a new approach to diabetes care designed specifically for remote communities. The IMPROVE SUGAR study is a national cluster-randomised trial evaluating an intensive diabetes management model for Aboriginal and Torres Strait Islander adults living with inadequately controlled Type 2 diabetes. The model combines culturally appropriate care, intensive lifestyle support and treatment with tirzepatide, a once-weekly medication.

Across five states and ten communities, 260 participants will be divided into standard and intensive care groups. The trial aims to determine whether this approach can improve blood sugar control, reduce diabetes-related complications and provide a sustainable model of care that can be adopted more broadly across remote communities.

The role of philanthropy

Funding from Hearts & Minds, as nominated by TDM Growth Partners, has helped Baker Heart and Diabetes Institute undertake critical early-stage activities, including community engagement, research collaborations, ethics approvals, and the recruitment of staff and participants. The study is now underway, with Site Initiation Visits successfully completed at Bidgerdii Rockhampton and Blackwater. These milestones pave the way for participant recruitment and trial delivery across participating communities.

What this could unlock

This project has the potential to reshape diabetes care for Aboriginal and Torres Strait Islander people living in regional and remote Australia. By testing a more accessible and culturally appropriate model of care, the research could reduce complications, improve quality of life and support better long-term health outcomes. The findings will provide important evidence to guide future diabetes treatment and care in remote communities across Australia. Closing the gap in health outcomes and life expectancy is, and always has been, the driving force behind this work.

Funding support from Hearts & Minds, as nominated by Core Fund Manager, TDM Growth Partners. For further information visit Baker Hearts and Diabetes Institute. This content was last updated in July 2026.

The challenge

Diabetes is a significant health challenge in remote communities, where access to healthcare can be limited and health outcomes are often worse than in the broader population.

According to the Australian Institute of Health and Welfare, diabetes has a significant health and economic impact in Australia, costing Australia's health system more than $4 billion each year. In remote communities, the burden is even greater, increasing the risk of serious complications including heart disease, kidney disease and premature death.

Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.

Project overview 

Researchers are testing a new approach to diabetes care designed specifically for remote communities. The IMPROVE SUGAR study is a national cluster-randomised trial evaluating an intensive diabetes management model for Aboriginal and Torres Strait Islander adults living with inadequately controlled Type 2 diabetes. The model combines culturally appropriate care, intensive lifestyle support and treatment with tirzepatide, a once-weekly medication.

Across five states and ten communities, 260 participants will be divided into standard and intensive care groups. The trial aims to determine whether this approach can improve blood sugar control, reduce diabetes-related complications and provide a sustainable model of care that can be adopted more broadly across remote communities.

The role of philanthropy

Funding from Hearts & Minds, as nominated by TDM Growth Partners, has helped Baker Heart and Diabetes Institute undertake critical early-stage activities, including community engagement, research collaborations, ethics approvals, and the recruitment of staff and participants. The study is now underway, with Site Initiation Visits successfully completed at Bidgerdii Rockhampton and Blackwater. These milestones pave the way for participant recruitment and trial delivery across participating communities.

What this could unlock

This project has the potential to reshape diabetes care for Aboriginal and Torres Strait Islander people living in regional and remote Australia. By testing a more accessible and culturally appropriate model of care, the research could reduce complications, improve quality of life and support better long-term health outcomes. The findings will provide important evidence to guide future diabetes treatment and care in remote communities across Australia. Closing the gap in health outcomes and life expectancy is, and always has been, the driving force behind this work.

Funding support from Hearts & Minds, as nominated by Core Fund Manager, TDM Growth Partners. For further information visit Baker Hearts and Diabetes Institute. This content was last updated in July 2026.

Disclaimer: This material has been prepared by Hearts & Minds, published on July 1, 2026. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Picture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt Call
July 1, 2026

Next generation CAR T-cell therapy for cancer

The Call Lab at WEHI is pioneering innovative approaches to find this ‘goldilocks zone’, making CAR T-cell therapy safer and more effective.

Read More
HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).
May 4, 2026

How science turned back the clock of human development to create a miracle blood stem cell

Many thought it could never be done. But three Murdoch Children’s Research Institute scientists recreated embryonic development to crack the blood stem cell code.

Read More
November 15, 2024

Professor Alex Brown in conversation with Professor Jason Kovacic

At the 2024 Sohn Hearts & Minds Conference, we heard from Professor Alex Brown in conversation with Professor Jason Kovacic about Indigenous heart health and genomics.

Read More

A/Professor Tim Sargeant | 2024 Sohn Hearts & Minds Conference

Associate Professor Tim Sargeant has been at SAHMRI (South Australian Health and Medical Research Institute) in Adelaide where he studies the role of lysosomes in Alzheimer’s disease.

Read More
July 1, 2026

Unlocking the mysteries of the human brain

The Sydney Brain Bank is helping researchers uncover the causes of neurodegenerative disease and build a future with better diagnosis, treatment and prevention.

Read More
Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.
July 1, 2026

A new approach to Parkinson’s Disease

Exploring nerve stimulation as a potential treatment.

Read More
Dr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds Conference
July 1, 2026

Revealing what drives PSP

Mapping the biological changes behind progressive supranuclear palsy in the brain.

Read More
Picture: Dr Jennifer SnaithPicture: Dr Jennifer SnaithPicture: Dr Jennifer SnaithPicture: Dr Jennifer Snaith
July 1, 2026

Advancing treatment options for type 1 diabetes

Improving blood glucose and reducing insulin needs.

Read More
July 1, 2026

Solving the genetic causes of autoimmune diseases

Mapping hundreds of risk markers to better understand how these diseases develop and progress

Read More
December 5, 2023

Prof Daniel MacArthur | 2023 Sohn Hearts & Minds Conference

At the 2023 Sohn Hearts & Minds Conference, we heard from Prof Daniel MacArthur, the Director of the Centre for Population Genomics.

Read More
December 5, 2023

Prof Michelle Simmons AO | Sohn Hearts & Minds Conference

At this year's Sohn Hearts & Minds Conference, we heard from Prof Michelle Simmons, the CEO and Founder of Silicon Quantum Computing.

Read More
December 5, 2023

Prof Misty Jenkins AO | 2023 Sohn Hearts & Minds Conference

At the 2023 Sohn Hearts & Minds Conference, we heard from Prof Misty Jenkins. Misty is a NHMRC fellow and laboratory head of the Immunology Division at the Walter and Eliza Hall Institute.

Read More
Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.
November 15, 2023

Advancing Medicine Is In Daniel MacArthur’s DNA

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Read More
November 10, 2023

Big thinkers in hunt for brain cancer cure

“Brain cancer is rare, but for people who do get it the prognosis is not good,” Assistant Professor Jenkins tells The Australian.

Read More
April 20, 2023

Artificial intelligence gives new hope for sufferers of severe heart problem

New AI software can improve the diagnosis of severe aortic stenosis by 72% and could potentially change the lives of about 50,000 Australians with the life-threatening condition.

Read More